Weil Institute of Critical Care Medicine, Rancho Mirage, CA, USA.
Crit Care Med. 2010 Nov;38(11):2175-80. doi: 10.1097/CCM.0b013e3181eedad6.
To investigate the effects of epinephrine when administered during either normothermic or therapeutic hypothermic cardiopulmonary resuscitation on postresuscitation myocardial and cerebral function and survival.
Prospective, randomized, placebo-controlled experimental study.
University-affiliated animal research laboratory.
Thirty-two healthy male Sprague-Dawley rats.
Ventricular fibrillation was induced and untreated for 8 mins. The animals were then randomly assigned to one of four groups: normothermic placebo control; normothermic epinephrine; hypothermic placebo control; and hypothermic epinephrine. Hypothermia was initiated coincident with the start of cardiopulmonary resuscitation. The blood temperature was reduced and maintained at 32 ± 0.2°C and continued for 4 hrs after resuscitation. Normothermic animals were maintained at 37 ± 0.2°C. Either placebo or epinephrine (20 μg/kg) was administered 5 mins after the start of cardiopulmonary resuscitation and 3 mins before defibrillation.
Postresuscitation cardiac output, ejection fraction, and myocardial performance index were measured hourly for 4 hrs after resuscitation; neurologic deficit scores were measured daily for 7 days, and durations of survival were observed for up to 3 mos. Except for three normothermic control animals, all animals were resuscitated. When epinephrine was administered during normothermic cardiopulmonary resuscitation, postresuscitation myocardial function was severely impaired when compared with the normothermic control group. However, postresuscitation myocardial function was significantly better in animals treated with epinephrine during hypothermic cardiopulmonary resuscitation when compared with hypothermic controls. This was associated with significantly fewer postresuscitation ventricular arrhythmias, less ST-segment elevation, better postresuscitation neurologic deficit scores, and longer duration of survival.
Epinephrine, when administered during normothermic cardiopulmonary resuscitation, significantly increases the severity of postresuscitation myocardial dysfunction and decreases the duration of survival. These detrimental effects of epinephrine, however, no longer exist when it is administered during therapeutic hypothermic cardiopulmonary resuscitation.
研究心肺复苏期间给予肾上腺素对复律后心肌和脑功能及存活率的影响。
前瞻性、随机、安慰剂对照的实验研究。
大学附属动物研究实验室。
32 只健康雄性 Sprague-Dawley 大鼠。
诱导心室颤动,不治疗 8 分钟。动物随后被随机分为四组之一:常温安慰剂对照;常温肾上腺素;低温安慰剂对照;低温肾上腺素。复律时开始低温。体温降低并维持在 32±0.2°C,复律后持续 4 小时。常温动物维持在 37±0.2°C。心肺复苏开始后 5 分钟和除颤前 3 分钟给予安慰剂或肾上腺素(20μg/kg)。
复苏后每小时测量心输出量、射血分数和心肌性能指数 4 小时;神经功能缺损评分每天测量 7 天,并观察最长 3 个月的存活时间。除了 3 只常温对照动物外,所有动物均复苏。在常温心肺复苏期间给予肾上腺素时,与常温对照组相比,复律后心肌功能严重受损。然而,在低温心肺复苏期间给予肾上腺素时,复律后心肌功能明显优于低温对照组。这与复律后室性心律失常减少、ST 段抬高减少、复律后神经功能缺损评分更好、存活时间更长有关。
在常温心肺复苏期间给予肾上腺素可显著增加复律后心肌功能障碍的严重程度并降低存活时间。然而,当在治疗性低温心肺复苏期间给予肾上腺素时,肾上腺素不再产生这些有害影响。